← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2012Last known activity
Nov 30, 2024
Timeline
2010s
- Jun 1, 2012
Atara Biotherapeutics— Founded
Drugs by trial phase (14 distinct, 17 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (7 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Communicable Diseases
- Cytomegalovirus Infections
- Endometrial Neoplasms
- Epstein-Barr Virus Infections
- Fallopian Tube Neoplasms
- Immunologic Deficiency Syndromes
- Infections
- Leiomyosarcoma
- Leukemia
- Lymphohistiocytosis, Hemophagocytic
- Lymphoma
- Lymphoproliferative Disorders
- Mesothelioma
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Myelodysplastic Syndromes
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Sclerosis
- Viremia
- Virus Diseases
Recent trials (27)
- NCT06429800OfficialPhase 1Nov 30, 2024
- NCT06429800Lead sponsorPhase 1Nov 30, 2024
- NCT06256484Lead sponsorPhase 1Jan 22, 2024
- NCT06256484OfficialPhase 1Jan 22, 2024
- NCT04554914Lead sponsorPhase 2Nov 30, 2020
- NCT04554914Study directorPhase 2Nov 30, 2020
- NCT04577326CollaboratorPhase 1Sep 30, 2020
- NCT03769467Study directorPhase 1/Phase 2Nov 28, 2018
- NCT03769467Lead sponsorPhase 1/Phase 2Nov 28, 2018
- NCT03392142Lead sponsorPhase 3Dec 29, 2017
- NCT03392142Study directorPhase 3Dec 29, 2017
- NCT03394365Lead sponsorPhase 3Dec 29, 2017
- NCT03394365Study directorPhase 3Dec 29, 2017
- NCT03283826Lead sponsorPhase 1Oct 19, 2017
- NCT03283826Study directorPhase 1Oct 19, 2017
Details
- Founded
- South San Francisco, CA, US Jun 1, 2012
- Last known activity
- Nov 30, 2024